Purine and pyrimidine metabolism: Convergent evidence on chronic antidepressant treatment response in mice and humans

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Park, Dong Ik ^a   Dournes, Carine ^a   Sillaber, Inge ^b   Uhr, Manfred ^a   Asara, John M ^c   Gassen, Nils C ^a   Rein, Theo ^a   Ising, Marcus ^a   Webhofer, Christian ^a   Filiou, Michaela D ^a   Müller, Marianne B ^a,d   Turck, Christoph W ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Phenoquest AG   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; PROTEOME; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL; ANIMAL BEHAVIOR; DBA MOUSE; DRUG EFFECTS; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; MALE; METABOLISM; METABOLOME; MOUSE; PATHOPHYSIOLOGY; SWIMMING; TIME FACTOR;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSIVE DISORDER, MAJOR; HIPPOCAMPUS; HUMANS; MALE; METABOLOME; MICE; MICE, INBRED DBA; PAROXETINE; PROTEOME; PURINES; PYRIMIDINES; SEROTONIN UPTAKE INHIBITORS; SWIMMING; TIME FACTORS;

EID: 84991087100     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35317     Document Type: Article

References (45)

1. Fredman, S. J. et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry 61, 403-408 (2000).
2. Laje, G., McMahon, F. J. Genome-wide association studies of antidepressant outcome: a brief review. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1553-1557 (2011).
3. Tansey, K. E. et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med. 9, e1001326 (2012).
4. Shinkai, K., Yoshimura, R., Ueda, N., Okamoto, K., Nakamura, J. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol 24, 11-17 (2004).
5. Kaddurah-Daouk, R. et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry 1, e26 (2011).
6. Sillaber, I. et al. Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berl. ) 200, 557-572 (2008).
7. Kaster, M. P. et al. The antidepressant-like effect of inosine in the FST is associated with both adenosine A1 and A 2A receptors. Purinergic Signal. 9, 481-486 (2013).
8. Gu, X. et al. Antidepressant-like effects of auraptenol in mice. Sci Rep 4, 4433 (2014).
9. Doucet, M. V., Levine, H., Dev, K. K., Harkin, A. Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice. Neuropsychopharmacology 38, 1575-1584 (2013).
10. Yoshimura, R. et al. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Hum Psychopharmacol 24, 489-494 (2009).
11. Mitchell, N. C., Gould, G. G., Smolik, C. M., Koek, W., Daws, L. C. Antidepressant-like drug effects in juvenile and adolescent mice in the tail suspension test: Relationship with hippocampal serotonin and norepinephrine transporter expression and function. Front Pharmacol 4, 131 (2013).
12. Olivier, J. D. A., Blom, T., Arentsen, T., Homberg, J. R. The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: A review. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1400-1408 (2011).
13. Wagner, K. V. et al. Differences in FKBP51 Regulation Following Chronic Social Defeat Stress Correlate with Individual Stress Sensitivity: Influence of Paroxetine Treatment. Neuropsychopharmacology 37, 2797-2808 (2012).
14. Malkesman, O. et al. The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. Biol. Psychiatry 67, 864-871 (2010).
15. Naviaux, J. C. et al. Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy. Transl Psychiatry 4, e400 (2014).
16. Lucae, S. et al. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum. Mol. Genet. 15, 2438-2445 (2006).
17. Renshaw, P. F. et al. Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. Am J Psychiatry 158, 2048-2055 (2001).
18. Carlezon, W. A. et al. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biol. Psychiatry 57, 343-350 (2005).
19. Brocardo, P. S., Budni, J., Kaster, M. P., Santos, A. R. S., Rodrigues, A. L. S. Folic acid administration produces an antidepressantlike effect in mice: evidence for the involvement of the serotonergic and noradrenergic systems. Neuropharmacology 54, 464-473 (2008).
20. Gilbody, S., Lewis, S., Lightfoot, T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am. J. Epidemiol. 165, 1-13 (2007).
21. Papakostas, G. I. et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, doubleblind, parallel-sequential trials. Am J Psychiatry 169, 1267-1274 (2012).
22. Webhofer, C. et al. Proteomic and metabolomic profiling reveals time-dependent changes in hippocampal metabolism upon paroxetine treatment and biomarker candidates. J Psychiatr Res 47, 289-298 (2013).
23. Zhao, J. et al. Metabolomic identification of biochemical changes induced by fluoxetine and imipramine in a chronic mild stress mouse model of depression. Sci Rep 5, 8890 (2015).
24. Zhang, Y. et al. Proteomic and metabolomic profiling of a trait anxiety mouse model implicate affected pathways. Mol. Cell Proteomics 10, M111. 008110 (2011).
25. Einat, H., Belmaker, R. H. The effects of inositol treatment in animal models of psychiatric disorders. J Affect Disord 62, 113-121 (2001).
26. Mukai, T., Kishi, T., Matsuda, Y., Iwata, N. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol 29, 55-63 (2014).
27. Wurglics, M., Schubert-Zsilavecz, M. Hypericum perforatum: a "modern" herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet 45, 449-468 (2006).
28. Herrera-Ruiz, M. et al. Antidepressant effect and pharmacological evaluation of standardized extract of flavonoids from Byrsonima crassifolia. Phytomedicine 18, 1255-1261 (2011).
29. Webhofer, C. et al. Metabolite profiling of antidepressant drug action reveals novel drug targets beyond monoamine elevation. Transl Psychiatry 1, e58 (2011).
30. Belzeaux, R. et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry 2, e185 (2012).
31. Hayashi-Takagi, A., Vawter, M. P., Iwamoto, K. Peripheral biomarkers revisited: integrative profiling of peripheral samples for psychiatric research. Biol. Psychiatry 75, 920-928 (2014).
32. Elfving, B. et al. Inverse correlation of brain and blood BDNF levels in a genetic rat model of depression. Int. J. Neuropsychopharmacol. 13, 563-572 (2010).
33. Svenningsson, P. et al. Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram. Mol. Psychiatry 19, 962-964 (2014).
34. Feng, L. et al. Subpathway-GMir: identifying miRNA-mediated metabolic subpathways by integrating condition-specific genes, microRNAs, and pathway topologies. Oncotarget 6, 39151-39164 (2015).
35. Li, J. et al. The detection of risk pathways, regulated by miRNAs, via the integration of sample-matched miRNA-mRNA profiles and pathway structure. J Biomed Inform 49, 187-197 (2014).
36. Hansen, K. F., Obrietan, K. MicroRNA as therapeutic targets for treatment of depression. Neuropsychiatr Dis Treat 9, 1011-1021 (2013).
37. Gurbuz Ozgur, B., Aksu, H., Birincioglu, M., Dost, T. Antidepressant-like effects of the xanthine oxidase enzyme inhibitor allopurinol in rats. A comparison with fluoxetine. Pharmacol Biochem Behav 138, 91-95 (2015).
38. Taguchi, R. et al. Selective corticotropin-releasing factor 1 receptor antagonist E2508 has potent antidepressant-like and anxiolyticlike properties in rodent models. Behav. Brain Res, doi: 10. 1016/j. bbr. 2016. 06. 017 (2016).
39. Guzzetti, S. et al. Strain differences in paroxetine-induced reduction of immobility time in the forced swimming test in mice: role of serotonin. Eur. J. Pharmacol. 594, 117-124 (2008).
40. Droy-Dupré, L. et al. Hierarchical clustering identifies a subgroup of colonic adenocarcinomas expressing crypt-like differentiation markers, associated with MSS status and better prognosis. Virchows Arch. 466, 383-391 (2015).
41. Muehlmann, A. M., Bliznyuk, N., Duerr, I., Lewis, M. H. Repetitive motor behavior: further characterization of development and temporal dynamics. Dev Psychobiol 57, 201-211 (2015).
42. Frank, E. et al. Stable isotope metabolic labeling with a novel N-enriched bacteria diet for improved proteomic analyses of mouse models for psychopathologies. PLoS ONE 4, e7821 (2009).
43. Weckmann, K., Labermaier, C., Asara, J. M., Müller, M. B., Turck, C. W. Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidates. Transl Psychiatry 4, e481 (2014).
44. Gassen, N. C. et al. Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice, and humans. PLoS Med. 11, e1001755 (2014).
45. Hiemke, C. et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44, 195-235 (2011).